Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06056596 · ClinicalTrials.gov registry record · Early Phase 1
Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
A Early Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT06056596: Clinical Trial Early Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT06056596 is a Early Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06056596, a Early Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to test whether an oral medication (lamivudine) enters the eye and reduces blood markers of inflammation in people who undergo retinal detachment surgery (pars plana vitrectomy). Participants will take the study medication or placebo, and the researchers will measure blood markers of inflammation before and after surgery. The researchers will also measure the amount of medication in the blood and fluid inside the participant's eye (which is collected during surgery).
Primary Outcome
Mean concentration of lamivudine in plasma
Interventions
- DRUG Placebo
- DRUG Lamivudine 300 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2024-09-06 |
| Phase | Early Phase 1 |
Why NCT06056596 stopped before completion
NCT06056596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06056596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06056596 about?
NCT06056596 is a clinical study titled "Lamivudine and Plasma Markers of Inflammation in Retinal Detachment". The goal of this clinical trial is to test whether an oral medication (lamivudine) enters the eye and reduces blood markers of inflammation in people who undergo retinal detachment surgery (pars plana vitrectomy). Participants will take the study medication or placebo, and the researchers will meas...
What is the current status of trial NCT06056596?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2024-01-30. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT06056596?
The interventions under investigation include: Placebo (DRUG), Lamivudine 300 MG (DRUG).
Who is sponsoring clinical trial NCT06056596?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06056596's enrollment target sits among peer trials
2 1973rd of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI